AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06337747 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional technique
Description: Subjects randomized to the traditional technique will receive 3cc of PLLA (per side, per treatment) in the anterior temporal region.
Study NCT06337747 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental technique
Description: Subjects randomized to the extended technique will receive 3cc of PLLA (per side, per treatment) in the anterior temporal region, as well as 2cc (per side, per treatment) in the posterior (i.e., behind the hairline) temporal region.
Study NCT04901234 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard radiotherapy +/- chemotherapy
Description: No radiotherapy adaptation unless major dosimetric deviation
Study NCT04901234 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Experimental radiotherapy +/- chemotherapy
Description: Systemic MRI-based radiotherapy adaptation mid-treatment
Study NCT05633589 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sc610 cell injection
Description: Peripheral blood mononuclear cells (PBMCs) obtained via apheresis are used for cell product preparation. PD-1 positive T cells are isolated from PBMCs, are transduced with lentivirus loaded with enhanced receptor and amplification factor, and cell quantity are amplified. The obtained Sc610 is used for one-time intravenous infusion.
Study NCT06304402 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Percussive Massage Treatment
Description: In the group where regional vibration is applied, the Hypervolt™ vibrating massage device (HYPERICE Inc, US) will be used. This device is a vibration device with five different speed settings, vibrating at 3,200 percussions per minute (HYPERICE Inc. 'Hypervolt' device. Retrieved from https://hyperice.com/hypervolt-bluetooth, Accessed on: 08.12.2021). The device offers five different head attachment options. For this study, the ball attachment option will be selected as it is the least aggressive option, and the vibration from the device will be applied to the relevant muscle body (Kayoda, 2019). For facilitatory effect, the application will be performed on the posterior deltoid for 5 minutes at a low frequency.
Study NCT06304402 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Proprioceptive Neuromuscular Facilitation Stretching
Description: Among the PNF stretching techniques, the muscle-relaxation technique will be applied. The athlete will be positioned in a side-lying posture on the treatment table with the dominant shoulder in the modified sleeper position, ensuring stabilization of the scapula on the table. The other arm will be positioned in extension along the body with the palm facing upwards. The participant will be instructed to actively bring the arm of the lower limb to the physiological barrier of internal rotation. At this point, they will be asked to perform maximum isometric contraction in external rotation for 7 seconds. After the isometric contraction, the muscle will be relaxed, and active-assisted stretching will be applied in internal rotation for 15 seconds. A 5-second rest will be provided between repetitions, and the exercise will consist of 5 repetitions.
Study NCT06180083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azelastine Hydrochloride/ Fluticasone propionate nasal spray
Description: A single dose \[four sprays (two sprays in each nostril)\] of Azelastine HCL/ Fluticasone Propionate 137 mcg/50 mcg Nasal Spray
Study NCT06180083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelastine Hydrochloride/ Fluticasone propionate nasal spray
Description: A single dose \[four sprays (two sprays in each nostril)\] of Azelastine HCL/ Fluticasone Propionate 137 mcg/50 mcg Nasal Spray
Study NCT06180083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 'DYMISTA' NASAL SPRAY
Description: A single dose \[four sprays (two sprays in each nostril)\] of 'DYMISTA' (AZELASTINE HYDROCHLORIDE/ FLUTICASONE PROPIONATE) NASAL SPRAY 137 Microgram/50 Microgram
Study NCT06180083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 'DYMISTA' NASAL SPRAY
Description: A single dose \[four sprays (two sprays in each nostril)\] of 'DYMISTA' (AZELASTINE HYDROCHLORIDE/ FLUTICASONE PROPIONATE) NASAL SPRAY 137 Microgram/50 Microgram
Study NCT05693324 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minority stress
Description: Intervention based on Cognitive Behavioural and Compassion Focused Treatments
Study NCT06323395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vizol S LIPID BALANCE eye drops
Description: 1 drop 4 times a day
Study NCT06323395 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ophthalmic saline eye drops
Description: 1 drop 4 times a day
Study NCT05054569 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Stress Management and Health Education
Description: Participants will attend group sessions with a trained facilitator held over videoconference. Sessions will each last 2 hours and will be held once weekly for 10 weeks. Sessions will include Cognitive-Behavioral Stress Management and health education content.
Study NCT06397209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Propioceptive Neuromascular facilitation
Description: Propioceptive Neuromascular Facilitation techniques will be given for 5 days/week,10 repetitions,30 minutes/day for 8 weeks
Study NCT06397209 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neural Flossing
Description: Neural Flossing exercises will be given for 5 days/week, 3 sets of 10 repetitions in 2 minutes for 30 minutes for 8 weeks
Study NCT04964167 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Plant extract
Description: Natural plant extract
Study NCT04964167 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Plant extract
Description: Natural plant extract
Study NCT04964167 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Plant extract
Description: Natural plant extract
Study NCT00183508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: Participants will learn cognitive behavioral strategies for symptom reduction
Study NCT00183508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: Participants will receive psychoeducation regarding common reactions to traumatic events
Study NCT04825925 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEB-BACE(Drug-eluting beads bronchial arterial chemoembolization)
Description: Bronchial arteriography was performed to find tumor-feeding artery. After the catheter had been inserted into the tumor-feeding artery, the Platinum was infused. BAI (Bronchial Arterial Infusion ) chemotherapy was followed by DEB-BACE(Drug-eluting beads bronchial arterial chemoembolization); the CalliSpheres loaded with Vinorelbine were infused into the tumor-feeding arteries until stasis or near-stasis of blood flow in the vessel was observed.
Study NCT05430113 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulator (octopolar Medtronic Vectris Leads)
Description: 2-4 leads FDA-approved for treatment of symptoms of refractory pain
Study NCT06364436 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reiki energy therapy
Description: In order to perform distance Reiki application, the practitioner must have completed Reiki II level training according to the Traditional Usui Reiki system and must be attuned by a person with a Usui Reiki Master and Teacher degree. With harmony, the energy channels in the individual's body are opened and the harmonious individual becomes a tool of universal healing energy.
Study NCT06543082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg
Description: Participants will take low-dose colchicine (0.6 mg once daily) in addition to ticagrelor maintenance therapy (90 mg twice daily), and discontinue aspirin the day after PCI. They will have an hs-CRP test 1 month after PCI. If the hs-CRP level is below 2 mg/L, colchicine will be discontinued 1 month after PCI. If it is 2 mg/L or higher, colchicine will be continued for 12 months after PCI.
Study NCT05880225 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reciprocal Imitation Training
Description: As a naturalistic developmental behavioral intervention (NDBI), Reciprocal Imitation Training (RIT) utilizes contingent imitation, linguistic mapping, modeling, prompting, and contingent reinforcement to train object and gesture imitation during play activities.
Study NCT05880225 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: music-enhanced Reciprocal Imitation Training
Description: Music-enhanced imitation training uses music and rhythm to enhance the predictability and salience of the strategies utilized within the Reciprocal Imitation Training platform (i.e., contingent imitation, linguistic mapping, modeling, prompting, and contingent reinforcement to train object and gesture imitation during play activities).
Study NCT05390385 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: KE1 5g
Description: 5g of KE1 (KetoneAid, Falls Church, VA), diluted to 4 ounces
Study NCT05390385 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: KE1 10g
Description: 10g of KE1 (KetoneAid, Falls Church, VA), equal to 4 ounces
Study NCT05390385 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: KE4 5g
Description: 5g of KE4 (KetoneAid, Falls Church, VA), diluted to 4 ounces
Study NCT06421987 — intervention group
Intervention type: DEVICE
Intervention: Near Infrared Spectroscopy (NIRS)
Description: NIRS is a portable, non-invasive, brain imaging device.
Study NCT04647305 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Closed face shield with Surgical face mask use
Description: Use of a closed face shield with a surgical face mask during daily activities. The educational intervention will provide recommendations on COVID-19 prevention and proper use of the closed face shield and the surgical face masks.
Study NCT04647305 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgical face mask use only
Description: Use of a surgical face mask during daily activities. The educational intervention will provide recommendations on COVID-19 prevention and the proper use of surgical face masks.
Study NCT05749861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348(5)
Description: QD, PO
Study NCT05749861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828, D097, D337
Description: QD, PO
Study NCT05874778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy
Description: All enrolled patients will first complete a total of 6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy (Rituximab + Cyclophosphamide + Doxorubicin + Prednisolone) and conduct evaluation about treatment effects (i.e. efficacy evaluation) once every 2 cycles, and after their completion of the 6th cycle, they will receive maintenance treatment . After the end of 6th cycle of treatment or after their leaving the group, efficacy evaluation is conducted every three months to obtain relevant data regarding the 2-year Progression-Free Survival(PFS) and survival of the subjects.
Study NCT05874778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy
Description: All enrolled patients will first complete a total of 6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy (Rituximab + Cyclophosphamide + Doxorubicin + Prednisolone) and conduct evaluation about treatment effects (i.e. efficacy evaluation) once every 2 cycles, and after their completion of the 6th cycle, they will receive maintenance treatment . After the end of 6th cycle of treatment or after their leaving the group, efficacy evaluation is conducted every three months to obtain relevant data regarding the 2-year Progression-Free Survival(PFS) and survival of the subjects.
Study NCT05874778 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy beyond standard R-CHOP Chemotherapy
Description: Radiotherapy: after completion of the standard R-CHOP treatment, enrolled patients will be divided into radiotherapy group and non-radiotherapy group. In radiotherapy group, further consolidation radiotherapy targeting patients' pre-treatment large masses or extranodal affected areas will be given, with routine segmentation of 30-36Gy/15-18f.
Study NCT05703152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Exercise
Description: Therapeutic exercise program will be applied that will include two modalities: aerobic and resistance exercise. The duration will be 8 weeks with a frequency of 3 sessions per week, with a duration per session of 60 minutes.
Study NCT06171035 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D-printed high-fidelity craniofacial manikin model education
Description: Slide-based presention plus 3D printed model
Study NCT06171035 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional model education
Description: Slide-based presention plus traditional model
Study NCT05390385 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: KE 10g
Description: 10g of KE4 (KetoneAid, Falls Church, VA), diluted to 4 ounces
Study NCT05390385 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: Flavor-matched control placebo drink (KetoneAid, Falls Church, VA), 4 ounces
Study NCT06324045 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deprescribing
Description: 1. The clinical pharmacist will review the patient's medications using validated screening tools, draft a deprescribing plan of the potential problematic medications, consult with the physician (MDT-CKD nephrologist), make the needed amendments, and document in the medical records.~2. The plan will be implemented and monitored during the patient's appointments for 1- 2 weeks at the center by the nephrologist.~3. The medication plan will be reconciled before discharge from dialysis or a planned appointment, and patients will be given a deprescribing card containing medication information. A note will be posted on CERNER as well. The primary care physician might also be contacted by the MDT-CKD team for consultation or any inquiries regarding the patient's condition or medications.~4. The MDT-CKD specialist nurse will conduct 3 post-appointment follow-up phone calls on day 2, day 7, and day 28 to enquire about any withdrawal symptoms or any concerns of the patient.
Study NCT04769375 — intervention group
Intervention type: OTHER
Intervention: Evaluation of pain
Description: The presence of pain localization pelvic girdle pain will be questioned in the body chart. Inaddition to this, the level of the pelvic girdle pain will be evaluated by visual analog scale.
Study NCT04769375 — intervention group
Intervention type: OTHER
Intervention: Application of pelvic girdle pain tests
Description: The tests will be applied sequentially to investigate the presence and severity of the pain (Tests: Posterior Pelvic Pain Provocation, Patriarch FABER, Long Dorsal Sacroiliac Ligament Pain Provocation, Simpsis Palpation, Modified Trendelenburg and Active Straight Leg Raise)
Study NCT04769375 — intervention group
Intervention type: OTHER
Intervention: Application of pelvic girdle questionnaire
Description: Pelvic girdle questionnaire will be filled by pregnant women with pelvic girdle pain.
Study NCT05005299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax is administered as an oral tablet once daily.
Study NCT05005299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is administered as an intravenous infusion at a dose of 30mg/m2 daily, to be administered over 30 minutes.
Study NCT05005299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is administered as an intravenous infusion at a dose of 750mg/m2 daily, to be administered over 30 minutes and to commence 1 hour after fludarabine infusion.
Study NCT05435911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REMIMAZOLAM BESYLATE 2.5 Mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, for SOLUTION [BYFAVO]
Description: Remimazolam Besylate is used as an intervention drug for general anesthesia, followed by flumazenil administration at the end of anesthesia, compared to propofol-based total intravenous anesthesia during breast cancer surgery under general anesthesia
Study NCT05435911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flumazenil
Description: Flumazenil is used as an additional intervention drug to facilitate emergence from general anesthesia in the Remimazolam with Flumazenil group.
Study NCT05435911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol is used as an active comparator drug for general anesthesia until the end of anesthesia, to be compared to remimazolam besylate during breast cancer surgery under general anesthesia.
Study NCT04416932 — intervention group
Intervention type: PROCEDURE
Intervention: Ultasound
Description: Evaluation of post-operative patients who have had total shoulder arthroplasty and will assess the integrity of the rotator cuff using ultrasound.
Study NCT04903899 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTATATE
Description: A weight-based activity of 200 MBq kg-1 will be used for the first dose. The activity of the second dose will be calculated based on whole body activity scans as well as SPECT CT scans to determine the absorbed kidney dose. The aim is to administer 177Lu-DOTATATE corresponding to a whole-body dose of 1,2 Gy, with a cumulative whole-body dose of about 2,4 Gy over two courses, and not exceeding a cumulative renal dose of 23 Gy, in order to avoid renal toxicity.
Study NCT05213442 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: To estimate the prevalence rates of liver disease in psychiatric inpatients and to explore factors associated with the existence of liver disease.
Description: Patients will receive the usual clinical and paraclinical examinations as part of their hospitalization diagnostic workup. For the biological analyses, a blood sample will be taken following inclusion as well as a Fibroscan examination.~Data will be collected from the patient, or if necessary from the health care team, using the medical record (interview and/or self-questionnaires).
Study NCT05097937 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham intervention
Description: The needle will be inserted into the right common extensor tendon of the epicondyle for 90 seconds without galvanic current.
Study NCT05097937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low intensity percutaneous electrolysis
Description: A single impact of galvanic current will be applied in the common extensor tendon of the epicondyle (right side) with an intensity of 0.3 mA for 90 seconds.
Study NCT05097937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity percutaneous electrolysis
Description: Three impacts of galvanic current will be applied in the common extensor tendon of the epicondyle (right side) with an intensity of 3 mA and a duration of 3 seconds each.
Study NCT05252936 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 vaccine social media campaign exposure
Description: A series of animated video clips will be promoted through Facebook Ads and randomized at the individual level across Facebook users throughout the entire country. To investigate the effectiveness of Mayan language content, we are testing three treatment arms - visually identical videos in the 1) Spanish, 2) K'iche', and 3) Kaqchikel languages. The videos are visually identical and follow the same audio script, translated into the three focal language. Local voiceover artists were used to record the scripts in the three languages. A control group that is not exposed to any of the social media campaign content will serve as active comparator to allow for comparison of outcomes with treatment arms.
Study NCT05252936 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine social media campaign exposure
Description: A series of animated video clips will be promoted through Facebook Ads and randomized at the individual level across Facebook users throughout the entire country. To investigate the effectiveness of Mayan language content, we are testing three treatment arms - visually identical videos in the 1) Spanish, 2) K'iche', and 3) Kaqchikel languages. The videos are visually identical and follow the same audio script, translated into the three focal language. Local voiceover artists were used to record the scripts in the three languages. A control group that is not exposed to any of the social media campaign content will serve as active comparator to allow for comparison of outcomes with treatment arms.
Study NCT06547788 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mitral valve repair with creation of an 8 mm inter-atrial shunt
Description: Mitral valve repair with creation of an 8 mm inter-atrial shunt
Study NCT06547788 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mitral valve repair with creation of an 8 mm inter-atrial shunt
Description: Mitral valve repair with creation of an 8 mm inter-atrial shunt
Study NCT05379153 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Therapy
Description: Undergo vaginal fractional CO2 laser therapy
Study NCT05379153 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Intervention
Description: Undergo placebo procedure
Study NCT05379153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05379153 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05379153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life Assessment
Description: Ancillary studies